About Shanghai Pharmaceuticals Holding Company

The company is a large pharmaceutical industry group listed in Shanghai and Hong Kong. The main business covers the pharmaceutical industry and commerce, and ranks among the Fortune 500 and the top 50 global pharmaceutical companies. Its comprehensive strength ranks in the top three Chinese pharmaceutical companies, and is selected as a constituent stock of the Shanghai Composite 180 Index, the Shanghai and Shenzhen 300 Index, and the Morgan Stanley China Index (MSCI). The company's main business covers the pharmaceutical industry and pharmaceutical business. The company's main pharmaceuticals (production) products: hydroxychloroquine sulfate tablets, injectable urastatin, tanshinone IIA sodium sulfonate injections, polysaccharide iron complex capsules, and bifidobacteria trifecta active bacterial preparations. Corporate honors: “2023 Asia Pacific Quality Organization - Innovation Award”, the company won 27 national quality awards, 112 provincial and municipal quality awards, the “Fortune 500” list, and won the “Top 50 Global Pharmaceutical Companies”, “Top 25 Global Pharmaceutical Brands”, “China's Top 100 Pharmaceutical Industry Companies”, and “China's Top 100 Pharmaceutical Industry Companies”, and “Best Industrial Enterprise in China's Pharmaceutical R&D Product Line”, ranked 473rd among the 2020 Fortune Global 500, and is one of only two Chinese pharmaceutical companies; In “Fortune It ranked 57th in the 2020 Fortune China 500 published by “Fortune” (Chinese version); ranked 1009th in the 2020 Global Top 2000 Companies published by “Forbes”; and ranked 2nd in the overall strength of China Pharmaceutical Group;